Biomarkers for acute and chronic graft versus host disease: state of the art.
Luisa GiacconeDanilo Giuseppe FaraciSara ButeraGiuseppe LiaClara Di VitoGiulia GabrielliMarco CerranoJacopo MariottiChiara DellacasaFrancesco FelicettiEnrico BrignardelloDomenico MavilioBenedetto BrunoPublished in: Expert review of hematology (2020)
In the near future, several validated biomarkers will be available to help clinicians in the diagnosis of GVHD, the identification of patients at high risk of GVHD development and in patients' stratification according to its severity. Then, immunosuppressive treatment could be tailored to each patient's real needs. However, more efforts are needed to achieve this goal. Although most of the proposed biomarkers currently lack validation with large-scale clinical data, their study led to improved knowledge of the biological basis of GVHD, and ultimately to implementation of GHVD treatment.
Keyphrases
- healthcare
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- newly diagnosed
- primary care
- ejection fraction
- chronic kidney disease
- electronic health record
- combination therapy
- big data
- acute lymphoblastic leukemia
- drug induced
- machine learning
- patient reported outcomes
- respiratory failure
- replacement therapy
- patient reported